Idecabtagene Vicleucel (Abecma), up to 460 Million Cells

Name: Negotiated commercial rates for Idecabtagene Vicleucel (Abecma), up to 460 Million Cells (HCPCS C9081), in Maryland
Creator: Tynbil
License: https://tynbil.com/terms

Maryland rates for HCPCS C9081

Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Rates by insurance carrier

Insurance Carrier	Facility/Professional	Modifier	Typical Low	Median	Typical High